;PMID: 10738270
;source_file_564.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..35] = [t:0..35]
;1)sentence:[e:40..118] = [t:40..118]
;2)section:[e:122..198] = [t:122..198]
;3)section:[e:202..296] = [t:202..296]
;4)sentence:[e:300..326] = [t:300..326]
;5)sentence:[e:327..423] = [t:327..423]
;6)sentence:[e:424..509] = [t:424..509]
;7)sentence:[e:510..518] = [t:510..518]
;8)sentence:[e:519..771] = [t:519..771]
;9)sentence:[e:773..781] = [t:773..781]
;10)sentence:[e:782..879] = [t:782..879]
;11)sentence:[e:880..997] = [t:880..997]
;12)sentence:[e:998..1010] = [t:998..1010]
;13)sentence:[e:1012..1130] = [t:1012..1130]
;14)section:[e:1134..1179] = [t:1134..1179]

;section 0 Span:0..35
;J Surg Oncol  2000 Mar;73(3):158-63
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..6] Surg) (NNP:[7..12] Oncol) (CD:[14..18] 2000)
        (CC:[19..26] Mar;73-LRB-) (CD:[26..27] 3) (-RRB-:[27..28] -RRB-)
        (CD:[28..32] :158) (::[32..33] -) (CD:[33..35] 63)))

;sentence 1 Span:40..118
;Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct
;cancer.
;[59..64]:gene-rna:"K-ras"
;[66..69]:gene-rna:"p53"
;[75..78]:gene-rna:"APC"
;[88..117]:malignancy:"extrahepatic bile duct cancer"
(SENT
  (NP-HLN
    (NP (NNS:[40..51] Aberrations))
    (PP (IN:[52..54] of)
      (NP (DT:[55..58] the)
        (NML
          (NML (NN:[59..64] K-ras)
            (NML-1 (-NONE-:[64..64] *P*)))
          (,:[64..65] ,)
          (NML (NN:[66..69] p53)
            (NML-1 (-NONE-:[69..69] *P*)))
          (,:[69..70] ,) (CC:[71..74] and)
          (NML (NN:[75..78] APC)
            (NML-1 (NNS:[79..84] genes))))))
    (PP (IN:[85..87] in)
      (NP (JJ:[88..100] extrahepatic)
        (NML (NN:[101..105] bile) (NN:[106..110] duct))
        (NN:[111..117] cancer)))
    (.:[117..118] .)))

;section 2 Span:122..198
;Suto T, Habano W, Sugai T, Uesugi N, Funato O, Kanno S, Saito K, Nakamura S.
(SEC
  (FRAG (NNP:[122..126] Suto) (NNP:[127..128] T) (,:[128..129] ,)
        (NNP:[130..136] Habano) (NNP:[137..138] W) (,:[138..139] ,)
        (NNP:[140..145] Sugai) (NNP:[146..147] T) (,:[147..148] ,)
        (NNP:[149..155] Uesugi) (NNP:[156..157] N) (,:[157..158] ,)
        (NNP:[159..165] Funato) (NNP:[166..167] O) (,:[167..168] ,)
        (NNP:[169..174] Kanno) (NNP:[175..177] S,) (NNP:[178..183] Saito)
        (NNP:[184..185] K) (,:[185..186] ,) (NNP:[187..195] Nakamura)
        (NNP:[196..198] S.)))

;section 3 Span:202..296
;Department of Surgery I, School of Medicine, Iwate Medical University,
;Morioka,  Iwate, Japan.
(SEC
  (FRAG (NNP:[202..212] Department) (IN:[213..215] of) (NNP:[216..223] Surgery)
        (NNP:[224..225] I) (,:[225..226] ,) (NNP:[227..233] School)
        (IN:[234..236] of) (NNP:[237..245] Medicine) (,:[245..246] ,)
        (NNP:[247..252] Iwate) (NNP:[253..260] Medical)
        (NNP:[261..271] University) (,:[271..272] ,) (NNP:[273..280] Morioka)
        (,:[280..281] ,) (NNP:[283..288] Iwate) (,:[288..289] ,)
        (NNP:[290..295] Japan) (.:[295..296] .)))

;sentence 4 Span:300..326
;BACKGROUND AND OBJECTIVES:
(SENT
  (NP (NN:[300..310] BACKGROUND) (CC:[311..314] AND) (NNS:[315..325] OBJECTIVES)
      (::[325..326] :)))

;sentence 5 Span:327..423
;The genetic alterations involved in extrahepatic bile  duct (EHBD) cancer are
;poorly understood.
;[363..400]:malignancy:"extrahepatic bile  duct (EHBD) cancer"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[327..330] The) (JJ:[331..338] genetic)
          (NNS:[339..350] alterations))
      (VP (VBN:[351..359] involved)
        (NP (-NONE-:[359..359] *))
        (PP-CLR (IN:[360..362] in)
          (NP
            (NML
              (NML (JJ:[363..375] extrahepatic) (NN:[376..380] bile)
                   (NN:[382..386] duct))
              (NML (-LRB-:[387..388] -LRB-) (NN:[388..392] EHBD)
                   (-RRB-:[392..393] -RRB-)))
            (NN:[394..400] cancer)))))
    (VP (VBP:[401..404] are)
      (ADVP (RB:[405..411] poorly))
      (VP (VBN:[412..422] understood)
        (NP-1 (-NONE-:[422..422] *))))
    (.:[422..423] .)))

;sentence 6 Span:424..509
;Our aim was to identify aberrations of  the K-ras, p53, and APC genes in EHBD
;cancer.
;[468..473]:gene-rna:"K-ras"
;[475..478]:gene-rna:"p53"
;[484..487]:gene-rna:"APC"
;[497..508]:malignancy:"EHBD cancer"
(SENT
  (S
    (NP-SBJ (PRP$:[424..427] Our) (NN:[428..431] aim))
    (VP (VBD:[432..435] was)
      (S-NOM-PRD
        (NP-SBJ (-NONE-:[435..435] *))
        (VP (TO:[436..438] to)
          (VP (VB:[439..447] identify)
            (NP
              (NP (NNS:[448..459] aberrations))
              (PP (IN:[460..462] of)
                (NP (DT:[464..467] the)
                  (NML
                    (NML (NN:[468..473] K-ras)
                      (NML-1 (-NONE-:[473..473] *P*)))
                    (,:[473..474] ,)
                    (NML (NN:[475..478] p53)
                      (NML-1 (-NONE-:[478..478] *P*)))
                    (,:[478..479] ,) (CC:[480..483] and)
                    (NML (NN:[484..487] APC)
                      (NML-1 (NNS:[488..493] genes)))))))
            (PP (IN:[494..496] in)
              (NP (NN:[497..501] EHBD) (NN:[502..508] cancer)))))))
    (.:[508..509] .)))

;sentence 7 Span:510..518
;METHODS:
(SENT
  (NP (NNS:[510..517] METHODS) (::[517..518] :)))

;sentence 8 Span:519..771
;We investigated  aberrations of these genes in 52 EHBD cancers using
;polymerase chain reaction  (PCR) single-strand conformation polymorphism
;analysis, followed by direct  sequence determination and a PCR restriction
;fragment length polymorphism assay.
;[569..581]:malignancy:"EHBD cancers"
;[588..598]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ (PRP:[519..521] We))
    (VP (VBD:[522..534] investigated)
      (NP
        (NP (NNS:[536..547] aberrations))
        (PP (IN:[548..550] of)
          (NP (DT:[551..556] these) (NNS:[557..562] genes))))
      (PP (IN:[563..565] in)
        (NP (CD:[566..568] 52)
           (NN:[569..573] EHBD) (NNS:[574..581] cancers)))
      (S-MNR
        (NP-SBJ (-NONE-:[581..581] *))
        (VP (VBG:[582..587] using)
          (NP
            (NP
              (NML
                (NML (NN:[588..598] polymerase) (NN:[599..604] chain)
                     (NN:[605..613] reaction))
                (NML (-LRB-:[615..616] -LRB-) (NN:[616..619] PCR)
                     (-RRB-:[619..620] -RRB-)))
              (NML
                (NML (JJ:[621..627] single) (HYPH:[627..628] -)
                     (NN:[628..634] strand))
                (NN:[635..647] conformation) (NN:[648..660] polymorphism))
              (NN:[661..669] analysis))
            (,:[669..670] ,)
            (VP (VBN:[671..679] followed)
              (NP (-NONE-:[679..679] *))
              (PP (IN:[680..682] by)
                (NP-LGS
                  (NP (JJ:[683..689] direct) (NN:[691..699] sequence)
                      (NN:[700..713] determination))
                  (CC:[714..717] and)
                  (NP (DT:[718..719] a)
                    (NML
                      (NML (NN:[720..723] PCR))
                      (NML (NN:[724..735] restriction) (NN:[736..744] fragment)
                           (NN:[745..751] length) (NN:[752..764] polymorphism)))
                    (NN:[765..770] assay)))))))))
    (.:[770..771] .)))

;sentence 9 Span:773..781
;RESULTS:
(SENT
  (NP (NNS:[773..780] RESULTS) (::[780..781] :)))

;sentence 10 Span:782..879
;The K-ras, p53, and APC genes were mutated in 9.6%, 32.7%, and 0% of  EHBD
;cancers, respectively.
;[786..791]:gene-rna:"K-ras"
;[793..796]:gene-rna:"p53"
;[802..805]:gene-rna:"APC"
;[852..864]:malignancy:"EHBD cancers"
(SENT
  (S
    (NP-SBJ-2 (DT:[782..785] The)
      (NML
        (NML (NN:[786..791] K-ras)
          (NML-1 (-NONE-:[791..791] *P*)))
        (,:[791..792] ,)
        (NML (NN:[793..796] p53)
          (NML-1 (-NONE-:[796..796] *P*)))
        (,:[796..797] ,) (CC:[798..801] and)
        (NML (NN:[802..805] APC)
          (NML-1 (NNS:[806..811] genes)))))
    (VP (VBD:[812..816] were)
      (VP (VBN:[817..824] mutated)
        (NP-2 (-NONE-:[824..824] *))
        (PP (IN:[825..827] in)
          (NP
            (NP
              (NP (CD:[828..831] 9.6) (NN:[831..832] %))
              (,:[832..833] ,)
              (NP (CD:[834..838] 32.7) (NN:[838..839] %))
              (,:[839..840] ,) (CC:[841..844] and)
              (NP (CD:[845..846] 0) (NN:[846..847] %)))
            (PP (IN:[848..850] of)
              (NP (NN:[852..856] EHBD) (NNS:[857..864] cancers)))))
        (,:[864..865] ,)
        (ADVP (RB:[866..878] respectively))))
    (.:[878..879] .)))

;sentence 11 Span:880..997
;Loss of heterozygosity at the p53 and APC gene loci  was identified in 15.6%
;and 38.5% of EHBD cancers, respectively.
;[880..902]:variation-type:"Loss of heterozygosity"
;[910..913]:gene-rna:"p53"
;[918..921]:gene-rna:"APC"
;[970..982]:malignancy:"EHBD cancers"
(SENT
  (S
    (NP-SBJ-3
      (NP (NN:[880..884] Loss))
      (PP (IN:[885..887] of)
        (NP
          (NP (NN:[888..902] heterozygosity))
          (PP (IN:[903..905] at)
            (NP (DT:[906..909] the)
              (NML
                (NML
                  (NML (NN:[910..913] p53)
                    (NML-2 (-NONE-:[913..913] *P*)))
                  (NML-1 (-NONE-:[913..913] *P*)))
                (CC:[914..917] and)
                (NML
                  (NML (NN:[918..921] APC)
                    (NML-2 (NN:[922..926] gene)))
                  (NML-1 (NNS:[927..931] loci)))))))))
    (VP (VBD:[933..936] was)
      (VP (VBN:[937..947] identified)
        (NP-3 (-NONE-:[947..947] *))
        (PP (IN:[948..950] in)
          (NP
            (NP
              (NP (CD:[951..955] 15.6) (NN:[955..956] %))
              (CC:[957..960] and)
              (NP (CD:[961..965] 38.5) (NN:[965..966] %)))
            (PP (IN:[967..969] of)
              (NP (NN:[970..974] EHBD) (NNS:[975..982] cancers)))))
        (,:[982..983] ,)
        (ADVP (RB:[984..996] respectively))))
    (.:[996..997] .)))

;sentence 12 Span:998..1010
;CONCLUSIONS:
(SENT
  (NP (NNS:[998..1009] CONCLUSIONS) (::[1009..1010] :)))

;sentence 13 Span:1012..1130
;Our results suggest that an unknown suppressor gene on 5q other than the APC 
;gene may be responsible for EHBD cancer.
;[1040..1063]:gene-rna:"unknown suppressor gene"
;[1067..1069]:variation-location:"5q"
;[1085..1088]:gene-rna:"APC"
;[1118..1129]:malignancy:"EHBD cancer"
(SENT
  (S
    (NP-SBJ (PRP$:[1012..1015] Our) (NNS:[1016..1023] results))
    (VP (VBP:[1024..1031] suggest)
      (SBAR (IN:[1032..1036] that)
        (S
          (NP-SBJ
            (NP
              (NP (DT:[1037..1039] an)
                 (JJ:[1040..1047] unknown) (NN:[1048..1058] suppressor)
                 (NN:[1059..1063] gene))
              (PP (IN:[1064..1066] on)
                (NP (NN:[1067..1069] 5q))))
            (ADJP
              (ADJP (JJ:[1070..1075] other))
              (PP (IN:[1076..1080] than)
                (NP (DT:[1081..1084] the) (NN:[1085..1088] APC)
                    (NN:[1090..1094] gene)))))
          (VP (MD:[1095..1098] may)
            (VP (VB:[1099..1101] be)
              (ADJP-PRD (JJ:[1102..1113] responsible)
                (PP (IN:[1114..1117] for)
                  (NP (NN:[1118..1122] EHBD) (NN:[1123..1129] cancer)))))))))
    (.:[1129..1130] .)))

;section 14 Span:1134..1179
;PMID: 10738270 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1134..1138] PMID) (::[1138..1139] :) (CD:[1140..1148] 10738270)
        (NN:[1149..1150] -LSB-) (NNP:[1150..1156] PubMed) (::[1157..1158] -)
        (NN:[1159..1166] indexed) (IN:[1167..1170] for)
        (NNP:[1171..1179] MEDLINE-RSB-)))
